邢唷> HJG欹 餜B/bjbj84xx*  814e$1 Z1\1\1\1\1\1\136Z\1-\1`1Z1Z1-0纔V鯼]:.F1101.\660060@\1\116  : D桍N1 xvz顅h孴D崺R啒遅 Target Diseases and Pathogens This RFP is focused on identifying new interventions in a small set of diseases of relevance to global health, considering strategic alignment with other funders and current investments within the NSFC and the Gates Foundation. Consequently, only proposals addressing these specific indications will be considered. Vaccines What we are looking for The goal of this challenge is to solicit novel concepts and candidates for vaccines that can serve as transformative tools in the efforts to prevent, control or eliminate diseases of our interest. We are particularly interested in approaches to induce unnatural immunity to pathogens to achieve long-lasting immunity across multiple strains, species and/or sub-species, utilizing recent advances made in structural biology, bioinformatics and molecular immunology. Our ultimate goal is to enable a path to move the best vaccine concepts and candidates into clinical development. The scope of vaccine concepts could include ideas specific to the subset of global health pathogens described below, or broad, paradigm-shifting concepts in vaccinology, should they also have potential applicability to those specific pathogens.Target pathogens: Human immunodeficiency virus only approaches that aimed at providing sustained protection will be considered Mycobacterium tuberculosis A few of the many options to be considered include: Applications of new knowledge of structure-based immunogen design. New approaches to target common antigenic components shared by multiple strains that may evolve over time and/or multiple species or sub-species Novel vaccine concepts that can prevent infection, and block transmission Novel vaccine concepts, targets and constructs inspired by new understanding about the mechanism by which a targeted organism induces protective immunity by the human host New vaccine concepts that target specific tissue or cell types for appropriate induction of local and systemic immunity Novel vaccines designed specifically for populations with high disease burden or risk of infection New experimental systems or models for rapidly testing vaccines and predicting their efficacyWe will not consider funding for: Projects not relevant to the diseases listed above Identification of antigens without preliminary proof or hypothesis that developing such antigens radically improves protective efficacy Projects targeting molecular pathways targeted by currently available antigens or adjuvants currently in clinical development Vaccine concepts not based on an explicit hypothesis or rationale for improved performance over those candidates currently in development Approaches that represent incremental improvements to conventional solutions Basic studies of pathogen or human biology without a clear component that tests the potential for translation into specific and practical health solutionsTherapeutics: What we are looking for: With this topic we also seek to explore new therapeutic options to treat infectious diseases and other conditions that disproportionately burden those living in low-resource settings. We are particularly interested in approaches that would target specific pathogen populations that are either bottlenecks in the pathogen抯 life-cycle or that are significant contributors to disease or transmission, but may be difficult to treat with current agents. Areas of focus include: exploiting novel sources of chemical diversity not typically found in conventional small molecule libraries, including novel chemical approaches to the manipulation and optimization of complex molecules and natural products; development and prosecution of screening approaches that target pathogens in a realistic environment; and taking advantage of recent scientific and technical advances for target identification, validation, and deconvolution.Target Diseases: Tuberculosis New agents or approaches with the potential for shortening treatment duration Malaria Plasmodium falciparum and Plasmodium vivax Liver-stage and gametocyte-active agents, and multi-stage active compounds Diarrheal Disease in infants caused by: Cryptosporidium hominis Cryptosporidium parvum A few of the many possible options to be considered include (non-exclusive): Development of assays which allow high-throughput screening of pathogenic organisms under conditions that reflect their natural in vivo environment Approaches to target typically challenging organisms e.g. intracellular or non-replicating M. tuberculosis, malaria parasite hypnozoites or gametocytes Development of broad and generalizable methods for the optimization of active natural compounds and other complex moleculesWe will not consider funding for: Proposals not directed at one of the pathogens/diseases included in the priority list above. Screening of natural product extracts or other unrefined sources of chemical matter Identification and prosecution of new drug targets without a clear rationale for how drugs against such targets would fill a gap in our current therapeutic armamentarium Basic research into pathogen biology without a compelling rationale for how such research can be rapidly translated into a new therapeutic discovery approach Community@B 鏇杖棧杖杖債鍘杖諗葒諊誾嚾誾杖杖諊誾諗嚾嚾囌h莚h莚@OJQJh莚h莚@OJQJh莚h莚@OJQJh莚h莚@堷OJQJh莚h莚@堽OJQJh莚h莚@堹OJQJh莚h莚@OJQJh莚h莚OJQJh8 whPY^CJOJQJaJh杶hPY^5丆JOJQJaJ-@B~z UpxnI$ & FWDa$gd莚m$$ & FdとWDa$gdPY^m$$ & FdとWDa$gd莚m$gd莚gd莚gd莚gdPY^ Uo箬箬坭舞坭汙鏈璐鄞淩篡篡璐坭篡篡枸璐坭鄞鄞坭筵戳坭坭ㄨ滆滆ㄨh莚h莚6丱JQJhPY^CJOJQJaJh莚h莚@OJQJh莚h莚@堼OJQJh莚h莚@OJQJh莚h莚@OJQJh莚h莚OJQJh莚h莚@OJQJ<uv篋囅捂倭未袤尜捂鎢媼鎢鎢唯潗儩v悵儛潈恑悵hh@堽OJQJhh@堹OJQJhh@OJQJhh@OJQJhhOJQJh莚CJOJQJaJh莚h莚@OJQJh莚h莚@堼OJQJh莚h莚OJQJh莚h莚@OJQJh莚h莚@OJQJh莚h莚@堽OJQJ)uv9:KX$$ & FdとWDa$gdm$$ & FdとWDa$gdm$$ & FdとWDa$gdm$gdgdgdgdPY^$ & FWDa$gd莚m$gd莚9:L{rsvwxy|}箬垠櫛捐茶茶茶茶茶摐摐摐摐摐姄湏湏湏渾渳t}h2h=b@h2h=b@h=bh覻h=b@堼h覻h=b@ h覻h=bhhCJOJQJaJhh6丱JQJhB*CJOJQJaJph$?`hh@OJQJhh@堷OJQJhhOJQJhh@OJQJ-$Ld{\rsF. /"/$/&/$ & F WDa$gd=bm$gd=bgdPY^$ & FWDa$gdm$gd$ & FdとWDa$gdm$$ & FdとWDa$gdm$..........".$.&.(.*.,...0.4.6.:.<.>.@.B.D.F.H.J.L.P.R.V.\.^.b.d.h.j.l.n.p.r.t.|.~.............../ /"/黝戾苠荀遘逵孱苠鑠宇鬻孱宇苠茴遘逵苠苠苠受遘鬻鬻苠苠鑠苡鑠苠鈴藉h=bhPY^CJOJQJaJh=bh1h=b@h2h=b@h2h=b@堼h2h=b@ h覻h=bUh2h=b@h2h=b@堽A based interventions aimed at improving adherence to drug treatment regimens; Development of broad-spectrum antibiotic or antiviral compounds.     "/$/&/(/,/./2/4/8/:/@/B/耜廩廩廩廩h_`jh_`U hPY^hLh5xhPY^CJOJQJaJ &/*/,/0/2/6/8//@/B/gd莚 6182P:p莚皞. 捌A!"#悹$悹%癝班 惄j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nHsH tHJ`J PY^ck噀 $1$a$ CJKH_HaJmH nHsH tHd@d 莚h槝 1$$dゐ@&a$)B*CJ KHOJPJQJ^JaJ ph6_tH d@d 莚h槝 2$$d(@&a$)B*CJKHOJPJQJ^JaJph6_tH JJ 莚h槝 3$$d@&5CJ \aJ $A $ 貫祂=刉[SOBiB 0nf恏> 莚0 yb鑜噀W[ CharCJKHPJaJtH .. 莚0yb鑜Fh噀,gCJaJ44 莚0 yb鑜Fh噀,g CharCJaJ88 莚 h槝 3 Char5丆J \乤J PK!倞[Content_Types].xml瑧薺0E鲄卸豶(ヘ微Iw},潯-j弰4 蛇w旄P-t#b螜{U畯銧擉T閁^h卍}悒)蛔*1P' 揯鬃W孱0)櫐T闉9<搇#ぼ$yi}佸;纞@囨(顚蹌H滖男u* D谞z內/0娗盃瘥 $ X3aZ⒁鑼,癉0j~3叨蝏溈~i>贗3縗`?/[G歿\!-跼k.搒曰..椃碼嬋?PK!ブх6 _rels/.rels剰蟡0 囷吔冄}Q頤%v/C/(h"脎O 劋秣=畫旂 毆免C?薶醰=偵叅%[xp啠{鄣_糚眩<10堎O糝瓸d焉襃E4b$q_槥6L籲R7`畯ㄉ趁0虨O,錏n7擫i鋌〃/鉙綈╡械根鑄PK!kytheme/theme/themeManager.xml 蘉 @醹愘7c(Eb菜CA菭覠圩邈7蕪諞K Y, 奺.埛饇,ㄚH,l崆駢x紗逫萻Q}#諓叚遞 值+!,較$j=婫W櫨)釫+& 8PK!mQtheme/theme/theme1.xml靁MoE#F{oc'vGuh覨盵糟x=逎zvg53Nj廐H垈z飴昛 $石I)*E阓酀欇鮊&IA!裎>秣羌3緓镹男>掤擱U蟇L0斈屵嚦z迃rx鰾脅稔h9T8奣/魁煜?鍃Y雒'蟸3S琦棌~蜩鶅O_|w)馉鎘圚t=乤+d NG1-Rl苼1諶J鴚T锠疢1Kｃ柩"o he浪撣幝絇L-憒%絎臙甴Y7'qP.\L姼=岟薲穛炷3I爋fi墸.帽墘BRb-J款P_p蒅 茛▍i㎏鷗郿訉h汧梚櫷o7;7Q嫵2染媱珼>a/銐翾>嶺厭W 藬霱卂膗H剄)薶 胺+:Vi豾4r態裶汐橌"r嫃!帓2l徠a麃C奲此U|嚮!8^顩8>軤仯,A魶壭眲V韙鄨讕厏ls囔14犁_=,澀返o聻TV 跥陲"苧鎎H唼灮'.4熯x薜躻-戲蹺鮸褾;氕衯躑`嘼3"G 'e\昮H柊O 話ㄩ恬愪'$劘i_wp伬 >*靺8魂i&丩Y%\鋁,楎謝視=矚伭壵阱綔 r6f 提3儲淭厥厰)橗:陋ZK誏玸ゅ&C 鏜兣軟0 [浪玴@註醏j扣7 媺耏咹唜Hi葷cT5A蕆跑@顢腍驇馴AZC硙i' RQ\m伕,zo,僩Q襲{Y\,Nψ/=溷ら嵿L _.跆嘫7C6韽-fS宄h62密"5咍麥罭H凾[X65太4X%Y龡豚殖2纅鷎h輩紳痠~tCKF#猥b +趙1m鑵4`眹!:U翞!昿5a:倊{4韒笫m蝘o 萎c杽8m泛D矹秔S槍姍豓1鋣?#S奿?3E'pS2疳W`る甸q]( ┻08樲w別 n撏A鯴[s枃)k8皓= Aa?R d趻刪c楿詠瞬d)#換ueb恾滿捷C!ず&i0福>4魫S7鋥z蟣 F箎 4sKvUKo瘸椒h垀1砵YU奧V蠬塔5U8錠k;譁潘鮈9堚寂皹D 荀 ?*|FL 迪鳡"A3兇伂>g類dm2iV值殍そ杕謌<殞r8[kv抶熞蠃p鎶sj,潩z傴礭[鑚堨叆Qv11縤u鈨-高0%M2羙J描3u舘%覎PK! 褠煻'theme/theme/_rels/themeManager.xml.rels剰M 0匃倃oo雍&輬協勪5 6?$Q祉 ,.嘺緳i粭澤c21h:闀q毩m胳嶡RN壻;d癭値o7g慘(M&$R(.1榬'J摐袏T鶂8V"＆A然蠬鱱}狇|$絙{朠除8塯/]As賲(⑵銻#洩L蔥漢倪PK-!倞[Content_Types].xmlPK-!ブх6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!mQtheme/theme/theme1.xmlPK-! 褠煻' theme/theme/_rels/themeManager.xml.relsPK] 84   "/B/$&/B/餷8# 咥臕@餒 0(  饞0(  養 S  ?{ *7\ctz*,-/02359*,-/02359 橷I 鍲 :_^棬豍w灨狼J(L蘤8\O|mR宂n湟媂gr澥,岹詌蘴X m拏燬 勑剺勑`剺﨩JQJo(佛 劆剺劆`剺﨩JQJo(佛刾剺刾`剺﨩JQJ^Jo(o 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 劋刓劋`刓﨩JQJo(佛 凥刓凥`刓﨩JQJo(n 勳刓勳`刓﨩JQJo(u 剱刓剱`刓﨩JQJo(l 4刓4`刓﨩JQJo(n 勜 刓勜 `刓﨩JQJo(u 剕 刓剕 `刓﨩JQJo(l  刓 `刓﨩JQJo(n 勀刓勀`刓﨩JQJo(u 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛劆剺劆`剺﨩JQJ^Jo(o 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю 勑剺勑`剺﨩JQJo(佛 劆剺劆`剺﨩JQJo(佛 刾剺刾`剺﨩JQJo(ю 凘 剺凘 `剺﨩JQJo(佛剺`剺﨩JQJ^Jo(o 勦剺勦`剺﨩JQJo(ю 劙剺劙`剺﨩JQJo(佛剙剺剙`剺﨩JQJ^Jo(o 凱剺凱`剺﨩JQJo(ю X m橷I 媂gJ(L8\Ow_^宂岹詌                                                                                  J縣2T嘵  -O ∟bB#(>$ r .*, i-{#/$v/G5Z6OJ7q@|oA>JL#V9WPY^)V`=b袯gak n.q馛)蚛_`;爄:J6~l K(祍錣FLtv102豝u$d!N@4&1e6@xpNbo &莚*,@(8pp@p.Unknown G* Times New Roman5Symbol3. * Arial7.爗 @Calibri;媅SOSimSun7燢@Cambria?= * Courier New;WingdingsA犽 BCambria Math qhBGBG( &( &!?!%),.:;>?]}    & 0 2 3 : !6"000 0 0 0000006:>兀﨑 =@\]^$([{  0 0 000000Y;[個r  2HP  $PPY^2!xxusernsfcfile@nsfc.gov.cn0         鄥燆鵒h珣+'遲0, px   $user Normal.dotmnsfcfile@nsfc.gov.cn2Microsoft Office Word@F#@鍾阘]@鍾阘](脹諟.摋+,0 X`lt| &     !"#$%&'()*+,-./012345689:;<=>@ABCDEFIRoot Entry Fp鯼]K1Table7WordDocument84SummaryInformation(7DocumentSummaryInformation8?CompObju  F#Microsoft Office Word 97-2003 文檔 MSWordDocWord.Document.89瞦